Bristol Myers Squibb has faced financial challenges due to patent cliffs, but new launches and a dividend program make it attractive. The company lost exclusivity for key products, impacting financial results and stock performance. Despite revenue declines, drugs like Eliquis and Opdivo continue to perform well. The approval of Opdivo Qvantig offers more convenience and flexibility for patients. Bristol Myers Squibb aims to launch new drugs to drive growth, especially in oncology. The company’s dividend yield is over 4.6%, appealing to dividend-seeking investors. Overall, Bristol Myers Squibb’s slow and steady approach may appeal to conservative investors in 2026.

Read more at Yahoo Finance: Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026?